Hosting Call Today at 5pm ET
CALGARY,
AB, May 31, 2022 /CNW/ - Nanalysis
Scientific Corp. ("the Company", TSXV:
NSCI, OTCQX:
NSCIF, FRA:
1N1), a leader in portable NMR
machines and MRI technology for healthcare and industrial
applications, releases its first quarter results ending
March 31, 2022. Chief Executive
Officer, Sean Krakiwsky and Chief
Financial Officer, Luke Caplette
will host a conference call at 5 P.M.
Eastern Time on May 31, 2022
to discuss the results. All interested parties are invited to join
this call.
"We are happy to have carried the momentum from the fourth
quarter into the new year and first quarter," said Sean Krakiwsky, Founder and CEO of
Nanalysis. "The fourth quarter is our strongest quarter of
the year, as I expected it to be in 2022. We showed sequential
increase in revenue from Q4 to Q1, which is a positive signal
for our company for the rest of 2022. As seen with our recent
service contract win, we are beginning to achieve synergies from
the specific M&A transactions we have completed, I'm proud to
say we have diversified our product and service offerings while
continuing to drive towards our vision."
Financial highlights for the three months ended March 31,
2022:
- For the three months ended March
31, 2022, the Company reported consolidated revenue of
$5,554K, an increase of $2,277K or 69% from the comparative period in
2021.
- Gross margin was 60% for the three months ended March 31, 2022 compared to 64% for the three
months ended March 31, 2021.
- Income before other items for the three months ended
March 31, 2022 was $210k versus $267k
compared to the same period last year.
- Net loss for the three months ended was $1,492K, as compared to the three month loss
March 31, 2021 of $467K.
- The Company had cash on hand of $19,179K, an undrawn credit facility of
$6,127K, working capital of
$18,530K and an undrawn government
contribution funding of $4,985K as of
March 31, 2022.
Recent strategic and operational highlights during and
subsequent to the first quarter of 2022 include:
- Awarded $160 Million
Multi Year Service and Maintenance Contract: The Company's
wholly-owned subsidiary K'(Prime) Technologies (KPrime) has won a
six year $160 million service and
maintenance contract with Canadian Air Transportation Security
Authority ("CATSA"), which includes a gradual phase in period of
approximately one year. Furthermore, it is common for these types
of contracts to be renewed for an additional five years, making it
a potential 11 year recuring revenue opportunity, with
inflation-based contractual price increases. The effective date of
the executed contract is May 25, 2022
and it expires on May 31, 2028.
- Announced $4,985,000 Funding
Contribution Commitment from the Canadian Government: The
funding is provided through Prairies Economic Development Canada's
Business Scale-up and Productivity program, which provides fast
growing tech firms with support to scale-up and enter new markets.
Nanalysis will draw down on the funds over the next three years
with interest-free repayments commencing on September 1,
2025.
- Closed Initial Equity Investment in Quad
Systems: Nanalysis paid 7,500,000
CHF to acquire a 43% ownership position and two of five
board seats in Quad Systems AG. Nanalysis has nominated two
Directors on the Board of Quad Systems: Sean Krakiwsky and René Lenggenhager.
Additionally, until July 1, 2023, Nanalysis has an option to
acquire 100% of the issued and outstanding shares (i.e. remaining
57%) of Quad Systems at a pre-set valuation formula in a
combination of cash and Nanalysis shares. During the Option Period,
Nanalysis has a right of first refusal on all debt and equity
offerings of Quad Systems.
- Executed an Upsized Public Offering and Non-Brokered Private
Placement For Gross Proceeds of $15,224,700. On February 11, 2022 the Company closed a best
efforts marketed public offering of common shares of the Company,
including the full exercise of the over-allotment option and a
non-brokered private placement of common shares for combined gross
proceeds of $15.2 million. Pursuant
to the terms of the public offering and non-brokered private
placement the Company issued 13,840,637 common shares.
- Closed of Acquisition of K'(Prime) Technologies Inc. in
early January, 2022: KPrime, a North American sales and
service company, with a particular focus on scientific
instrumentation for pharma, food, chemical and oil & gas
customers, as well as imaging systems for security applications is
being integrated into the Company.
Operating Results
For the three months ended March 31,
2022, the Company reported consolidated revenue of
$5,554K, an increase of $2,277K or 69% from the comparative period in
2021. The increase from Q1 prior year can be attributed to the
shipment of more units of the 100MHz, coupled with revenue from the
recent acquisition, KPrime. Gross profit for the three months ended
March 31, 2022 was $3,345K (a margin of 60%) compared to gross
profit of $2,122K (a margin of 64%)
for the three months ended March 31,
2021. The Company's net loss for the three months ended was
$1,492K, as compared to the
three-month loss March 31, 2021 of
$467K. The increased loss was due to
higher costs, specifically sales and marketing expenses, increased
general and administration expenses and increased research and
development expenses, both in the Nanalysis segment and from the
new acquisitions. In addition, there were business acquisition
costs from the two transactions completed in the quarter, increased
depreciation and amortization expense, increased finance expense
partially offset by no RS2D earnout in the quarter and increased
revenues.
Outlook
"As we have laid out publicly, the Company's main objective this
year is to make the intrinsic value we've created by our recent
acquisitions manifest to shareholders. Combined with our ongoing
organic innovation, we believe that by the end of 2022, it will
become clear that we have positioned the company for solid growth
for years to come, with a strong economic moat, and a motivated
team energized for the future! Operational excellence is our most
important mantra, as we continue to leverage existing customer
relationships, in addition to our technologies, to fuel growth. So
the rest of 2022 is about consolidation, execution and capitalizing
on synergies. Then, in 2023, we'll resume acquisitions and
strategic activity. I am incredibly enthusiastic about the
challenges immediately before us, and the opportunities that lay on
the other side of those challenges."
"The Company plans to continue to expand business with a full
sales and service offering which has been substantially augmented
through our KPrime acquisition. With Quad Systems, we are
currently rolling out magnetic resonance ("MR") modules and will
have a full system to pursue the high-field part of the MR market
later this year. This broadens and complements our benchtop NMR
products. With products, service and sales we are moving towards
our goal," said Mr. Krakiwsky.
Conference Call
Investors interested in participating on the live call can dial
1-888-664-6392 or 416-764-8659 from abroad. Investors can also
access the call online through a listen-only webcast here:
https://app.webinar.net/NMnWA6QxEr9, or on the investor
relations section of the Company's website HERE.
The webcast will be archived on the Company's investor relations
webpage for at least 90 days and a telephonic playback will be
available for seven days after the conference call by calling
1-888-390-0541 or 416-764-8677, conference ID # 991626.
About Nanalysis Scientific
Corp. (TSXV: NSCI, OTCQX: NSCIF, FRA:1N1)
Nanalysis trades on the TSX Venture Exchange (TSXV)
in Canada with ticker symbol 'NSCI', OTC and
the Frankfurt exchange under the ticker symbol '1N1'. The
company's business is what we term "MRI and NMR for industry". The
company develops and manufactures portable Nuclear Magnetic
Resonance (NMR) spectrometers or analyzers for laboratory and
industrial markets. The NMReady-60™ was the first full-feature
portable NMR spectrometer in a single compact enclosure requiring
no liquid helium or any other cryogens. The company has followed-up
that initial offering with new products and continues to have a
strong innovation pipeline. Nanalysis recently announced that it
has begun selling a 100MHz device in 2020. The Company's new device
will be the most powerful and most advanced compact NMR device ever
brought to market.
Nanalysis devices are used in many industries (oil and gas,
chemical, mining, pharma, biotech, flavor and fragrances,
agrochemicals, law enforcement, and more) as well as numerous
government and university research labs around the world. The
Company continues to exploit new global market opportunities
independently and with partners.
With the recent acquisition of K'Prime, the company maintains a
North American sales and service company of over 40 individuals who
cover scientific instrumentation for pharma, food, chemical and oil
& gas customers, as well as imaging systems for security
applications.
Additionally, the Company has a 43% ownership in Quad Systems AG
("Quad Systems"), with an option to purchase the remaining
shares. Quad Systems is a Zurich-based Nuclear Magnetic
Resonance (NMR) company focused on high-field NMR for
pharmaceutical and other vertical markets.
Notice regarding Forward Looking
Statements and Legal Disclaimer
This news release contains certain "forward-looking statements"
within the meaning of such statements under applicable securities
law. Forward-looking statements are frequently characterized by
words such as "anticipates", "plan", "continue", "expect",
"project", "intend", "believe", "anticipate", "estimate", "may",
"will", "potential", "proposed", "positioned" and other similar
words, or statements that certain events or conditions "may" or
"will" occur. These statements are only predictions. Various
assumptions were used in drawing the conclusions or making the
projections contained in the forward-looking statements throughout
this news release. Forward-looking statements are based on the
opinions and estimates of management at the date the statements are
made and are subject to a variety of risks and uncertainties and
other factors that could cause actual events or results to differ
materially from those projected in the forward-looking statements.
The Company is under no obligation, and expressly disclaims any
intention or obligation, to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise, except as expressly required by applicable law.
Neither TSX Venture Exchange nor its Regulation Services
Provider accepts responsibility for the adequacy or accuracy of
this release.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/nanalysis-reports-first-quarter-2022-results-301557801.html
SOURCE Nanalysis Scientific Corp.